386 related articles for article (PubMed ID: 35897753)
1. Characterization of SARS-CoV-2 Escape Mutants to a Pair of Neutralizing Antibodies Targeting the RBD and the NTD.
Peter AS; Grüner E; Socher E; Fraedrich K; Richel E; Mueller-Schmucker S; Cordsmeier A; Ensser A; Sticht H; Überla K
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897753
[TBL] [Abstract][Full Text] [Related]
2. A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants.
Haslwanter D; Dieterle ME; Wec AZ; O'Brien CM; Sakharkar M; Florez C; Tong K; Rappazzo CG; Lasso G; Vergnolle O; Wirchnianski AS; Bortz RH; Laudermilch E; Fels JM; Mengotto A; Malonis RJ; Georgiev GI; Quiroz JA; Wrapp D; Wang N; Dye KE; Barnhill J; Dye JM; McLellan JS; Daily JP; Lai JR; Herbert AS; Walker LM; Chandran K; Jangra RK
mBio; 2021 Oct; 12(5):e0247321. PubMed ID: 34607456
[TBL] [Abstract][Full Text] [Related]
3. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
[TBL] [Abstract][Full Text] [Related]
4. Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant.
Graham C; Seow J; Huettner I; Khan H; Kouphou N; Acors S; Winstone H; Pickering S; Galao RP; Dupont L; Lista MJ; Jimenez-Guardeño JM; Laing AG; Wu Y; Joseph M; Muir L; van Gils MJ; Ng WM; Duyvesteyn HME; Zhao Y; Bowden TA; Shankar-Hari M; Rosa A; Cherepanov P; McCoy LE; Hayday AC; Neil SJD; Malim MH; Doores KJ
Immunity; 2021 Jun; 54(6):1276-1289.e6. PubMed ID: 33836142
[TBL] [Abstract][Full Text] [Related]
5. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike.
Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC
mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants.
Yi C; Sun X; Lin Y; Gu C; Ding L; Lu X; Yang Z; Zhang Y; Ma L; Gu W; Qu A; Zhou X; Li X; Xu J; Ling Z; Xie Y; Lu H; Sun B
Genome Med; 2021 Oct; 13(1):164. PubMed ID: 34649620
[TBL] [Abstract][Full Text] [Related]
7. Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants.
Tai W; Wang Y; Fett CA; Zhao G; Li F; Perlman S; Jiang S; Zhou Y; Du L
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795425
[TBL] [Abstract][Full Text] [Related]
8. Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape.
Wang L; Shi W; Chappell JD; Joyce MG; Zhang Y; Kanekiyo M; Becker MM; van Doremalen N; Fischer R; Wang N; Corbett KS; Choe M; Mason RD; Van Galen JG; Zhou T; Saunders KO; Tatti KM; Haynes LM; Kwong PD; Modjarrad K; Kong WP; McLellan JS; Denison MR; Munster VJ; Mascola JR; Graham BS
J Virol; 2018 May; 92(10):. PubMed ID: 29514901
[TBL] [Abstract][Full Text] [Related]
9. A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern.
Yuan M; Chen X; Zhu Y; Dong X; Liu Y; Qian Z; Ye L; Liu P
J Virol; 2022 Aug; 96(16):e0077522. PubMed ID: 35916510
[TBL] [Abstract][Full Text] [Related]
10. Neutralizing Monoclonal Anti-SARS-CoV-2 Antibodies Isolated from Immunized Rabbits Define Novel Vulnerable Spike-Protein Epitope.
Makdasi E; Levy Y; Alcalay R; Noy-Porat T; Zahavy E; Mechaly A; Epstein E; Peretz E; Cohen H; Bar-On L; Chitlaru T; Cohen O; Glinert I; Achdout H; Israely T; Rosenfeld R; Mazor O
Viruses; 2021 Mar; 13(4):. PubMed ID: 33810465
[TBL] [Abstract][Full Text] [Related]
11. The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against viral variants.
Makdasi E; Zvi A; Alcalay R; Noy-Porat T; Peretz E; Mechaly A; Levy Y; Epstein E; Chitlaru T; Tennenhouse A; Aftalion M; Gur D; Paran N; Tamir H; Zimhony O; Weiss S; Mandelboim M; Mendelson E; Zuckerman N; Nemet I; Kliker L; Yitzhaki S; Shapira SC; Israely T; Fleishman SJ; Mazor O; Rosenfeld R
Cell Rep; 2021 Sep; 36(10):109679. PubMed ID: 34464610
[TBL] [Abstract][Full Text] [Related]
12. Characterization of a Broadly Neutralizing Monoclonal Antibody against SARS-CoV-2 Variants.
Zakir TS; Meng T; Carmen LCP; Chu JJH; Lin RTP; Prabakaran M
Viruses; 2022 Jan; 14(2):. PubMed ID: 35215823
[TBL] [Abstract][Full Text] [Related]
13. Binding and neutralizing abilities of antibodies towards SARS-CoV-2 S2 domain.
Gao X; Fan L; Zheng B; Li H; Wang J; Zhang L; Li J; Zhu F
Hum Vaccin Immunother; 2022 Nov; 18(5):2055373. PubMed ID: 35417303
[TBL] [Abstract][Full Text] [Related]
14. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization.
Planas D; Veyer D; Baidaliuk A; Staropoli I; Guivel-Benhassine F; Rajah MM; Planchais C; Porrot F; Robillard N; Puech J; Prot M; Gallais F; Gantner P; Velay A; Le Guen J; Kassis-Chikhani N; Edriss D; Belec L; Seve A; Courtellemont L; Péré H; Hocqueloux L; Fafi-Kremer S; Prazuck T; Mouquet H; Bruel T; Simon-Lorière E; Rey FA; Schwartz O
Nature; 2021 Aug; 596(7871):276-280. PubMed ID: 34237773
[TBL] [Abstract][Full Text] [Related]
15. Crucial Mutations of Spike Protein on SARS-CoV-2 Evolved to Variant Strains Escaping Neutralization of Convalescent Plasmas and RBD-Specific Monoclonal Antibodies.
Ding C; He J; Zhang X; Jiang C; Sun Y; Zhang Y; Chen Q; He H; Li W; Xie J; Liu Z; Gao Y
Front Immunol; 2021; 12():693775. PubMed ID: 34484190
[TBL] [Abstract][Full Text] [Related]
16. Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines.
Cao Y; Yisimayi A; Bai Y; Huang W; Li X; Zhang Z; Yuan T; An R; Wang J; Xiao T; Du S; Ma W; Song L; Li Y; Li X; Song W; Wu J; Liu S; Li X; Zhang Y; Su B; Guo X; Wei Y; Gao C; Zhang N; Zhang Y; Dou Y; Xu X; Shi R; Lu B; Jin R; Ma Y; Qin C; Wang Y; Feng Y; Xiao J; Xie XS
Cell Res; 2021 Jul; 31(7):732-741. PubMed ID: 34021265
[TBL] [Abstract][Full Text] [Related]
17. Glycan Masking of Epitopes in the NTD and RBD of the Spike Protein Elicits Broadly Neutralizing Antibodies Against SARS-CoV-2 Variants.
Lin WS; Chen IC; Chen HC; Lee YC; Wu SC
Front Immunol; 2021; 12():795741. PubMed ID: 34925381
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2.
Amanat F; Thapa M; Lei T; Ahmed SMS; Adelsberg DC; Carreño JM; Strohmeier S; Schmitz AJ; Zafar S; Zhou JQ; Rijnink W; Alshammary H; Borcherding N; Reiche AG; Srivastava K; Sordillo EM; van Bakel H; ; Turner JS; Bajic G; Simon V; Ellebedy AH; Krammer F
Cell; 2021 Jul; 184(15):3936-3948.e10. PubMed ID: 34192529
[TBL] [Abstract][Full Text] [Related]
19. Computational Analysis of Mutations in the Receptor-Binding Domain of SARS-CoV-2 Spike and Their Effects on Antibody Binding.
Bozdaganyan ME; Shaitan KV; Kirpichnikov MP; Sokolova OS; Orekhov PS
Viruses; 2022 Jan; 14(2):. PubMed ID: 35215888
[TBL] [Abstract][Full Text] [Related]
20. Risk of rapid evolutionary escape from biomedical interventions targeting SARS-CoV-2 spike protein.
Van Egeren D; Novokhodko A; Stoddard M; Tran U; Zetter B; Rogers M; Pentelute BL; Carlson JM; Hixon M; Joseph-McCarthy D; Chakravarty A
PLoS One; 2021; 16(4):e0250780. PubMed ID: 33909660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
